Your browser doesn't support javascript.
loading
One Health drivers of antibacterial resistance: Quantifying the relative impacts of human, animal and environmental use and transmission.
Booton, Ross D; Meeyai, Aronrag; Alhusein, Nour; Buller, Henry; Feil, Edward; Lambert, Helen; Mongkolsuk, Skorn; Pitchforth, Emma; Reyher, Kristen K; Sakcamduang, Walasinee; Satayavivad, Jutamaad; Singer, Andrew C; Sringernyuang, Luechai; Thamlikitkul, Visanu; Vass, Lucy; Avison, Matthew B; Turner, Katherine M E.
Afiliação
  • Booton RD; Bristol Veterinary School, University of Bristol, Bristol, UK.
  • Meeyai A; Department of Epidemiology, Mahidol University, Bangkok, Thailand.
  • Alhusein N; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, UK.
  • Buller H; Bristol Medical School, University of Bristol, Bristol, UK.
  • Feil E; College of Life and Environmental Sciences, University of Exeter, Exeter, UK.
  • Lambert H; Department of Biology & Biochemistry, University of Bath, Bath, UK.
  • Mongkolsuk S; Bristol Medical School, University of Bristol, Bristol, UK.
  • Pitchforth E; Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok, Thailand.
  • Reyher KK; College of Medicine and Health, University of Exeter, Exeter, UK.
  • Sakcamduang W; Bristol Veterinary School, University of Bristol, Bristol, UK.
  • Satayavivad J; Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand.
  • Singer AC; Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.
  • Sringernyuang L; UK Centre for Ecology & Hydrology, Wallingford, UK.
  • Thamlikitkul V; Faculty of Social Sciences and Humanities, Mahidol University, Bangkok, Thailand.
  • Vass L; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Turner KME; School of Cellular & Molecular Medicine, University of Bristol, Bristol, UK.
One Health ; 12: 100220, 2021 Jun.
Article em En | MEDLINE | ID: mdl-33644290
ABSTRACT

OBJECTIVES:

Antibacterial resistance (ABR) is a major global health security threat, with a disproportionate burden on lower-and middle-income countries (LMICs). It is not understood how 'One Health', where human health is co-dependent on animal health and the environment, might impact the burden of ABR in LMICs. Thailand's 2017 "National Strategic Plan on Antimicrobial Resistance" (NSP-AMR) aims to reduce AMR morbidity by 50% through 20% reductions in human and 30% in animal antibacterial use (ABU). There is a need to understand the implications of such a plan within a One Health perspective.

METHODS:

A model of ABU, gut colonisation with extended-spectrum beta-lactamase (ESBL)-producing bacteria and transmission was calibrated using estimates of the prevalence of ESBL-producing bacteria in Thailand. This model was used to project the reduction in human ABR over 20 years (2020-2040) for each One Health driver, including individual transmission rates between humans, animals and the environment, and to estimate the long-term impact of the NSP-AMR intervention.

RESULTS:

The model predicts that human ABU was the most important factor in reducing the colonisation of humans with resistant bacteria (maximum 65.7-99.7% reduction). The NSP-AMR is projected to reduce human colonisation by 6.0-18.8%, with more ambitious targets (30% reductions in human ABU) increasing this to 8.5-24.9%.

CONCLUSIONS:

Our model provides a simple framework to explain the mechanisms underpinning ABR, suggesting that future interventions targeting the simultaneous reduction of transmission and ABU would help to control ABR more effectively in Thailand.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article